Diabetes Diabetes Drug Class Linked to Bile Duct and Gallbladder Disease

Article HTML
                    <!-- wp:heading -->
<h2 class="wp-block-heading">Type 2 Diabetes Drugs</h2>
<!-- /wp:heading -->

<!-- wp:paragraph -->
<p>A popular class of drugs used to treat type 2 diabetes may increase the risk of bile duct and gallbladder disease.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>The class, GLP-1 (glucagon-like peptide 1) receptor agonists, is given via an injection and includes Byetta (exenatide), Victoza (liraglutide) and Trulicity (dulaglutide).</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Health records of more than 1.5 million patients with type 2 diabetes in the United States, the United Kingdom and Canada who were taking an antidiabetic medication were examined in the study, which was published in <a href="https://archinte.jamanetwork.com/article.aspx?articleid=2540537" target="_blank" rel="noreferrer noopener">JAMA Internal Medicine</a>.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>GLP-1s were shown to cause a 79% increased risk of developing symptoms associated with bile duct and gallbladder disease compared to those not on any diabetes drug. Put another way, about 3 more patients per 1,000 exhibited symptoms compared to those not taking the medication. The most common adverse effect seen in this population were gallstones.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>Another class of diabetes drugs, DPP-4 (dipeptidyl peptidase 4) inhibitors, which are given as a pill and act in a similar way as GLP-1s, did not have the increased risk of bile duct and gallbladder disease. DPP-4s on the market include Januvia (sitagliptin), Onglyza (saxagliptin) and Tradjenta (linagliptin).</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>However, both GLP-1s and DPP-4s were not associated with an increased risk of acute pancreatitis.</p>
<!-- /wp:paragraph -->

<!-- wp:paragraph -->
<p>“It’s important that clinicians and patients alike be well informed about possible adverse effects,” Laurent Azoulay, PhD, a senior investigator at the Lady Davis Institute at the Jewish General Hospital in Montreal and the study’s lead author, said in a statement. “As a result of the gallbladder finding, it would be prudent for doctors to warn their patients to seek treatment if they experience symptoms, such as pain in their right side.”</p>
<!-- /wp:paragraph -->                    
     
                

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *

No comments yet. Be the first to comment!